sngx stock: Soligenix (SNGX) Company Profile

SNGX (Soligenix, Inc.)

sngx stock refers to the NASDAQ-traded common stock of Soligenix, Inc., ticker symbol SNGX. This article provides a comprehensive overview of Soligenix’s business focus on rare-disease therapeutics and public-health/biodefense platforms, the company’s clinical pipeline, platform technologies, market and trading characteristics of sngx stock, and where to find authoritative filings and investor resources.

Reader benefit: After reading you will understand what sngx stock represents, the core programs and platforms behind Soligenix, how the equity typically trades as a micro-cap biotech, the main risks and catalysts to watch, and where to verify primary documents and live market quotes.

Company overview

Soligenix, Inc. (SNGX) is a clinical-stage biopharmaceutical company headquartered in Princeton, New Jersey. Founded with a mission to develop products addressing rare diseases and public health threats, Soligenix operates through clinical and platform development focused on two complementary business segments: Specialized BioTherapeutics (therapeutic candidates for orphan and dermatology indications) and Public Health Solutions (vaccines and biodefense products leveraging stabilization and immunological platforms).

sngx stock represents ownership in Soligenix as the company advances a small portfolio of clinical-stage assets and platform technologies aimed at niche indications where regulatory designations and unmet need can create discrete value inflection points.

Corporate history and milestones

• Founding and purpose: Soligenix was established to advance therapeutics and biodefense countermeasures through translational research and platform innovation. The firm has a history of focusing on orphan indications and stabilization technologies for biologics.
• Public listing: sngx stock is listed on the NASDAQ exchange under the ticker SNGX. The public listing provides transparent market pricing and publicly available regulatory filings for investors to review.
• Platform and pipeline milestones: Over its corporate history, Soligenix has advanced multiple candidates into clinical trials and expanded platform capabilities including photodynamic therapy approaches and the ThermoVax thermal stabilization technology for vaccines and biologics.
• Financing events: As is common for clinical-stage biotechs, Soligenix has completed multiple financings (public offerings, private placements, and at-the-market offerings) to fund clinical programs and platform development. These capital raises typically affect share count and investor dilution considerations relevant to sngx stock holders.

(For the most recent corporate history updates and milestone dates, consult the company’s investor relations materials and SEC filings.)

Business operations and products

Soligenix’s operations are organized around two primary areas:

• Specialized BioTherapeutics: This segment focuses on therapeutic candidates for dermatologic and rare-disease indications, including photodynamic therapy and small-molecule immunomodulators under clinical development.
• Public Health Solutions: This segment includes vaccine candidates and technologies for biodefense and pandemic preparedness, notably a thermal stabilization platform intended to enable vaccine distribution without a strict cold chain.

Manufacturing and development activities emphasize compliance with U.S. regulatory standards, and the company has historically pursued U.S.-based manufacturing transfers and contract manufacturing relationships to align scale-up and GMP supply with clinical and regulatory needs.

Therapeutic pipeline and lead products

Soligenix’s pipeline contains programs derived from its core technologies. Major programs (names and clinical status summarized generically below) historically associated with the company include:

• HyBryte™ (SGX301): A photodynamic therapy candidate developed primarily for the treatment of cutaneous T-cell lymphoma (CTCL). HyBryte uses a topical photosensitizer activated by a specific light source to target diseased skin. Clinical development history includes early- and mid-stage trials; the program’s regulatory and commercialization path is a primary clinical focus for the company.

• SGX302: An investigational product exploring photodynamic approaches in dermatology, including potential indications such as psoriasis. The program leverages similar topical activation concepts and is positioned in early development stages.

• SGX945 (dusquetide): An investigational immune-modulating candidate previously studied in contexts such as oral mucositis and infectious or inflammatory conditions. Historical studies have informed safety and mechanism insights for the company’s immunomodulatory strategies.

• RiVax™: A ricin toxin vaccine candidate developed as a biodefense countermeasure. RiVax and related approaches are part of Soligenix’s public health portfolio and benefit from platform and regulatory interactions relevant to countermeasure development.

• ThermoVax® platform: A proprietary thermal stabilization technology designed to maintain vaccine and biologic potency at elevated temperatures, aimed at improving distribution logistics for vaccines and enabling stockpiles that are less dependent on cold-chain infrastructure.

Note: Clinical status, trial phases, and enrollment updates for these programs can change rapidly. For the most current trial-phase designations and registrational plans, refer to the company’s recent press releases and clinical trial registries.

Platform technologies and manufacturing

Key proprietary platforms include:

• Photodynamic therapy (PDT) platform: Used for topical activation approaches like HyBryte™. PDT couples a photosensitizer with a controlled light source to produce localized therapeutic effects, minimizing systemic exposure.

• ThermoVax® thermal stabilization: A formulation and process platform intended to stabilise vaccines and biologics at higher temperatures without losing potency. The platform targets logistical challenges in public health stockpiling and vaccine delivery.

Manufacturing considerations: Soligenix aims to work with qualified contract manufacturing organizations (CMOs) and pursue manufacturing transfers to U.S.-based facilities where appropriate to meet clinical and regulatory requirements. GMP-compliant supply and validated stabilization processes are essential for late-stage trials and potential commercialization.

Stock and market information

sngx stock trades on the NASDAQ exchange under ticker SNGX and is denominated in U.S. dollars (USD). As a clinical-stage biotechnology company with a focused pipeline, SNGX typically exhibits micro-cap characteristics: smaller market capitalization compared with large-cap pharmaceutical companies, lower average daily trading volume, wider bid-ask spreads, and higher price volatility.

Micro-cap traits often associated with sngx stock include:

• Market-cap sensitivity: Market capitalization may be small relative to larger biopharma peers, and news or milestone updates can produce sharp price moves.
• Liquidity constraints: Lower daily volume can mean reduced liquidity, leading to higher transaction costs for larger orders.
• Binary clinical risk: A small number of assets often drive valuation, leading to high dependence on clinical readouts and regulatory decisions.

Historical and current market data

This section explains the typical market-data fields investors monitor for sngx stock. Actual figures change in real time; always verify live quotes from authoritative market-data providers.

Common fields to check for sngx stock:

• Last traded price (USD) — reflects the most recent trade price on NASDAQ.
• 52-week high / 52-week low — a view of the share-price range over the prior year.
• Day range — intraday high and low.
• Volume and average volume — current day traded shares and average daily traded volume over a fixed lookback (e.g., 30-day average).
• Market capitalization — current market value equal to outstanding shares multiplied by market price.
• Shares outstanding — dilution metric used to compute market cap and per-share figures.
• Real-time quote caveats — many public market data feeds include delays; verify timestamps.

As a reminder, financial and market-data figures for sngx stock must be referenced with a timestamp. For example: 截至 2026-01-27，据 Nasdaq 报道，投资者应以当日实时行情为准并参考公司披露的最新数据。

Trading characteristics and liquidity

Retail and institutional investors should consider the following when evaluating sngx stock:

• Average daily volume: Lower average volume often leads to larger price impact for sizable buy/sell orders.
• Bid-ask spreads: Micro-cap equities can carry relatively wide spreads, increasing implicit transaction costs.
• Volatility: Clinical-stage biotech equities may exhibit high volatility around announcements such as trial enrollment updates, safety signals, regulatory designations, or partnership agreements.
• Order execution: Limit orders are commonly used by traders of micro-cap stocks to manage execution price risk.

If you plan to trade sngx stock, consider execution and custody options available on regulated broker/platform providers. When discussing execution, note that Bitget offers stock trading services and custody solutions; for those using web3 wallets, Bitget Wallet is the recommended option in Bitget’s ecosystem.

Financials and key metrics

As a clinical-stage developer, Soligenix historically has limited commercial revenue and relies on financing, grants, and collaborations to support R&D and operations. Key financial metrics to review in SEC filings and earnings releases include:

• Recent revenue (if any) and revenue sources (e.g., government contracts, grants, collaborative funding)
• Cash and cash equivalents — a key liquidity metric indicating runway for ongoing trials
• Net loss — common for companies primarily in R&D mode
• R&D expense — indicative of development intensity
• Shares outstanding and basic/diluted EPS (P/E typically not meaningful for pre-revenue biotech)
• Price-to-book, enterprise value, and other capital structure measures where applicable

Because sngx stock price and company-reported figures change over time, always use the timestamped disclosures in the company’s quarterly (Form 10-Q) and annual (Form 10-K) filings for authoritative numbers.

Recent quarterly results and balance sheet highlights

For current quarter results and balance sheet highlights, consult the latest investor presentation and SEC filings. Public-company press releases and earnings releases summarize:

• Cash on hand and cash runway estimates: These estimates typically assume current burn rate and do not forecast future financings.
• Net loss and operating expenses: R&D and G&A expense breakdowns appear in quarterly statements.
• Progress milestones and associated spend: Clinical trial costs and platform development expenses are material line items.

As an example framing statement (not a live figure): 截至 2026-01-27，据 company investor relations 报道，Soligenix 在其最近季度披露中提供了现金储备和研发支出的概况；投资者应参阅官方财务报表以获取精确数值。

Corporate governance and management

Soligenix’s governance structure comprises an executive management team and a board of directors with industry and scientific experience. Key leadership roles typically include the CEO, CFO, chief scientific officer (CSO), and heads of clinical development and regulatory affairs. For current executive names and biographies, review the company’s investor relations materials and proxy statements.

Board oversight and management experience are relevant to strategy execution, clinical development decisions, and capital allocation that influence sngx stock valuation.

Insider and institutional ownership

Common ownership categories to review for sngx stock include:

• Insider ownership: holdings by officers and directors, relevant for alignment of interests and potential insider transactions.
• Institutional ownership: positions held by funds and institutional investors, which can affect liquidity and investor support.
• Recent insider activity: insider buys or sells filed in Form 4 can signal leadership’s view of valuation but should be interpreted cautiously.

For a detailed ownership breakdown and recent insider transactions for sngx stock, consult SEC filings and market-data platforms that aggregate institutional holdings and Form 4 disclosures.

Regulatory, clinical and corporate developments

Regulatory and clinical events drive much of the near-term news flow for a company like Soligenix. Typical items to watch include:

• FDA designations (e.g., orphan drug, fast-track, or breakthrough therapy): These can affect regulatory timelines and incentives.
• Trial starts, enrollment milestones, and top-line readouts: Each trial update is a potential catalyst for sngx stock.
• Safety or efficacy updates and data presentations: Clinical readouts at conferences or in publications provide important context.
• Corporate actions: capital raises (public offerings, at-the-market programs), licensing deals, partnerships, or restructuring.
• Compliance notices: Nasdaq listing compliance or other regulatory matters are material for public investors.

When reading press releases, note the date. For example: 截至 2026-01-27，据 company press releases 报道，任何新的临床或监管进展将通过公司公告和SEC披露及时更新。

News, analyst coverage and market commentary

SNGX draws coverage from a range of market-data aggregators and social finance platforms. Sources that aggregate market and analyst commentary include major quote providers and retail-investor communities. Typical sources where coverage and sentiment for sngx stock may appear include firm investor relations releases, Nasdaq quote pages, Google Finance, major news outlets, and investor community platforms.

• Aggregate news services and market-data pages provide headlines, quotes, and recent press release listings for sngx stock.
• Retail-focused platforms and communities host investor conversation and sentiment but may include unverified posts and should be treated accordingly.

As of 2026-01-27, investors seeking aggregated coverage of sngx stock may consult market-data pages and the company’s IR materials for verified announcements. 截至 2026-01-27，据 CNN Markets、Nasdaq 和公司官网披露的公告，相关资讯以公司正式公告为准。

Risks and controversies

Investing in a clinical-stage micro-cap biotech such as Soligenix involves multiple risk factors. Key risks typically include (but are not limited to):

• Clinical trial failure risk: Clinical programs may fail to meet efficacy or safety endpoints, which can materially impact sngx stock price.
• Regulatory risk: Approvals depend on regulatory review and may involve additional requirements, delays, or rejections.
• Cash and financing risk: Limited cash and the need for future financings can lead to dilution of existing sngx stock holders.
• Liquidity and volatility: Low trading volume and higher volatility increase trading risk and execution costs.
• Concentration risk: A small pipeline means company value is often tied to one or a few key programs.
• Operational and manufacturing risk: Difficulties in scaling manufacturing or achieving validated supply for trials can delay programs.

Controversy and litigation risk: Like other public companies, Soligenix may face litigation or disputes that could impact reputation or finances; review SEC filings and press releases for any material legal notices.

This section is factual and not exhaustive; see the company’s public filings for a formal list of risks.

Investment considerations

This profile is informational and not investment advice. When considering sngx stock, market participants commonly weigh the following:

• Potential upside: Successful clinical readouts, regulatory approvals, commercialization, or strategic partnerships can create material value for shareholders.
• Potential downside: High binary risk associated with clinical outcomes, potential dilution from capital raises, and micro-cap liquidity constraints.

Practical points for investors and analysts:

• Use primary sources: Review SEC filings (10-Q, 10-K, 8-K), company press releases, and clinical registries for accurate data.
• Monitor cash runway: Track reported cash balances and planned spend to estimate financing needs.
• Follow clinical calendar: Trial enrollment updates and expected readout dates are key catalysts for sngx stock.
• Execution and manufacturing: Progress on GMP supply and manufacturing transfers may precede late-stage development.

If you choose to trade sngx stock, consider platform choice and execution strategy. Within Bitget’s ecosystem, users can access regulated trading services and custody solutions; Bitget Wallet is recommended when interacting with web3-enabled products offered by Bitget.

SEC filings and investor relations

Primary sources for authoritative information on Soligenix and sngx stock include:

• SEC EDGAR filings: Form 10-K (annual report), Form 10-Q (quarterly report), Form 8-K (material events), and Form 4 (insider transactions).
• Company investor relations (IR): press releases, investor presentations, and corporate governance materials.

When reporting market or financial figures, always include the date stamp of the underlying disclosure. For example: 截至 2026-01-27，据 SEC EDGAR 披露的最近一份 10-Q 报告，读者应以该报告披露的数值为准。

See also

• Clinical-stage biotech investing
• NASDAQ microcap stocks and liquidity considerations
• Comparative companies in rare-disease therapeutics and dermatology

References

This article was compiled from company disclosures and market-data aggregators. Primary reference categories used in preparing this profile include:

• Company investor relations materials and official press releases
• SEC filings (annual, quarterly, and current reports)
• Market-data providers and quote pages (Nasdaq, Google Finance, MSN, Yahoo Finance)
• News and aggregator coverage (major financial news platforms and monitored investor community sites)
• Retail investor discussion boards and social data aggregators (for market sentiment context)

Specific: 截至 2026-01-27，据 Nasdaq 报道并结合公司IR披露，读者应以公司发布的最新SEC文件与交易所挂牌信息为准。

External links

(References only — no clickable URLs are provided here.)

• Soligenix, Inc. — Official company website and Investor Relations
• SEC EDGAR — Company filings for Soligenix, Inc.
• NASDAQ — Quote page for SNGX
• Google Finance — Quote and basic metrics for SNGX
• Yahoo Finance — Symbol lookup and historical data
• Major market-data aggregators and news outlets for ongoing coverage

Notes on sources and timeliness

• Market data and quoted metrics for sngx stock change continuously. Always confirm live price, market-cap, and volume from an authoritative market-data provider or your brokerage prior to making any trade decision.
• Financial and clinical details should be verified in primary documents: the company’s SEC filings and press releases, and clinical registries for trial-specific data.
• This article contains informational summaries and neutral descriptions only. It does not constitute investment advice or a recommendation to buy or sell sngx stock.

Actionable next steps

• For verified, time-stamped market quotes for sngx stock, consult NASDAQ or your trading platform and check the company’s most recent SEC filings for financials and risk disclosures.
• To trade or custody equities including SNGX through a regulated provider, explore Bitget’s stock trading services and custody options; for web3 wallet needs, consider Bitget Wallet as an integrated solution.

Note: This profile is intended to be a factual, reference-style overview of sngx stock and Soligenix, Inc. For any trading decisions, rely on up-to-date primary disclosures and consult a licensed professional as needed.